Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a carbon neutral crypto ETPs, a solution for climate-neutral blockchain investments, as a new Swiss ETP issuer. Helveteq along with Swiss FinTech Innovation Lab of
Tags :Slider
On April 7, 2022, Credit Suisse completed its registered offering of USD 2.5 billion aggregate principal amount of senior notes. The offering consisted of USD 2.1 billion aggregate principal amount of 3.700% senior notes due 2025 and USD 400 million aggregate principal
Walder Wyss acted as Swiss counsel and Listing Agent to Montana Aerospace on the closing of the purchase of S.R.I.F. NV (the Asco Group) and the issuance and listing of 4,431,600 shares on 7
Bcomp, lightweighting specialists, closed its oversubscribed Series B financing round of CHF 32.4 million (USD 35 m). The round was led by automotive OEM venture funds BMW i Ventures and included a group of mobility
Niederer Kraft Frey advised the ED&F Man Group and its Swiss subsidiary Volcafe on its restructuring, cross-border USD 1.5 billion refinancing and in connection with the implementation of its UK restructuring plan. Established in 1783,
British oil and gas company BP has sold its Swiss retail business to Oel-Pool, suppliers of liquid fuels. The Swiss company together with its subsidiary company Moveri will officially take over BP’s gas station
Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a
Climeworks signs an equity round of CHF 600 million (USD 650 million). The financing is co-led by Partners Group (acting on behalf of its clients) and GIC, with further participation from Baillie Gifford, Carbon Removal Partners, Global
Walder Wyss and Heussen law firm, Munich, represented client Terra Quantum, a Swiss based quantum technology company, in an extension of its series A financing round in a total amount of USD 75 million.
Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding’
